Turkish Journal of Gastroenterology
Original Article

A comparison of the effects of infliximab, adalimumab, and pentoxifylline on rats with non-alcoholic steatohepatitis

1.

Dokuz Eylül University, Faculty of Medicine, Division of Gastroenterology, İzmir, Turkey

2.

Dokuz Eylül University, Faculty of Medicine, Division of Animal Laboratory, İzmir, Turkey

3.

Dokuz Eylül University, Faculty of Medicine, Division of Pathology, İzmir, Turkey

4.

Dokuz Eylül University, Faculty of Medicine, Division Haematolgy, İzmir, Turkey

Turk J Gastroenterol 2014; 25: 167-175
DOI: 10.5152/tjg.2014.5121
Read: 493 Downloads: 94 Published: 25 July 2019

Abstract

Background/Aims: Non-alcoholic steatohepatitis (NASH) lacks effective medical treatment.Since tumor necrosis factor alpha (TNF-α) plays an important role in NASH pathogenesis, we aimed to investigate drugs affecting TNF-α as possible treatment options during the development of NASH.

 

Materials and Methods: A total of 35 rats were divided into five groupsand evaluated over a 6week period. One group received a normal diet alone or in combination with the administration of infliximab, adalimumab or pentoxifylline

 

Results: NASH was successfully established in the MCD diet group. Levels of TNF-α were effectively suppressed in the three groups that received anti-TNF agents. No statistically significant differences were observed between the three agents in terms of the histological NASH score.

 

Conclusion: Our study showed that the anti-TNF agents infliximab, adalimumab, and pentoxifylline effectively suppress TNF-α. Although these drugs did not prevent the development of NASH, they were able to slightly reverse the NASH histopathology score and positively affect liver function tests.

Files
EISSN 2148-5607